RadioNano Therapeutics

Solution

As a drug discovery venture originating from Kyoto University, we are developing RN-501, a novel boron-containing drug for boron-neutron capture therapy (BNCT), a next-generation cancer radiation therapy targeting intractable cancers. Through proprietary boron carbide nanoparticle technology and polyglycerol modification, RN-501 achieves high tumor selectivity and accumulation, along with potent cancer-killing and immune-activating effects with a single intravenous administration, overcoming the limitations of existing drugs. As Japan's first and the world's first nano-BNCT drug, we aim for early societal implementation.